EE200000147A - April - uus kasvuefekte omav valk - Google Patents

April - uus kasvuefekte omav valk

Info

Publication number
EE200000147A
EE200000147A EEP200000147A EEP200000147A EE200000147A EE 200000147 A EE200000147 A EE 200000147A EE P200000147 A EEP200000147 A EE P200000147A EE P200000147 A EEP200000147 A EE P200000147A EE 200000147 A EE200000147 A EE 200000147A
Authority
EE
Estonia
Prior art keywords
april
new growth
growth protein
protein
new
Prior art date
Application number
EEP200000147A
Other languages
English (en)
Estonian (et)
Inventor
Tschopp Jurg
Original Assignee
Biogen, Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Incorporated filed Critical Biogen, Incorporated
Publication of EE200000147A publication Critical patent/EE200000147A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EEP200000147A 1997-09-12 1998-09-11 April - uus kasvuefekte omav valk EE200000147A (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5878697P 1997-09-12 1997-09-12
US7938498P 1998-03-26 1998-03-26
PCT/US1998/019191 WO1999012965A2 (en) 1997-09-12 1998-09-11 April- a novel protein with growth effects

Publications (1)

Publication Number Publication Date
EE200000147A true EE200000147A (et) 2001-02-15

Family

ID=26738027

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000147A EE200000147A (et) 1997-09-12 1998-09-11 April - uus kasvuefekte omav valk

Country Status (20)

Country Link
US (3) US20030138884A1 (ru)
EP (1) EP1027431A2 (ru)
JP (1) JP2001515712A (ru)
KR (1) KR100618492B1 (ru)
CN (1) CN1195849C (ru)
AU (1) AU759717B2 (ru)
BR (1) BR9812634A (ru)
CA (1) CA2303615A1 (ru)
CZ (1) CZ294615B6 (ru)
EA (1) EA005411B1 (ru)
EE (1) EE200000147A (ru)
HU (1) HUP0004611A3 (ru)
IL (1) IL134537A0 (ru)
IS (1) IS5378A (ru)
NO (1) NO20001242L (ru)
NZ (1) NZ503850A (ru)
PL (1) PL339463A1 (ru)
SK (1) SK3542000A3 (ru)
TR (1) TR200000669T2 (ru)
WO (1) WO1999012965A2 (ru)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217788B2 (en) 1996-03-14 2007-05-15 Human Genome Sciences, Inc. Human tumor necrosis factor delta polypeptides
US6541224B2 (en) 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
AU1700999A (en) * 1997-11-26 1999-06-15 Eli Lilly And Company Tnf ligand family gene
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
KR100834809B1 (ko) 1999-01-25 2008-06-05 바이오겐 아이덱 엠에이 인코포레이티드 Ｂａｆｆ, 관련 차단제 및 면역 반응에서 ｂ 세포와면역글로불린을 촉진 및 억제하는데에 있어서 이들의 용도
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
PL207501B1 (pl) * 1999-08-17 2010-12-31 Apotech R & D Sa Zastosowanie polipeptydu BCMA oraz przeciwciała skierowanego przeciwko BCMA
WO2001025256A2 (en) * 1999-10-06 2001-04-12 University Of Utah Research Foundation Trdl-1-gamma, a novel tumor necrosis-like ligand
UA74798C2 (ru) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Способ лечения рака у млекопитающих с помощью полипептида, который препятствует взаимодействию между april и его рецепторами
EP1259544B1 (en) 2000-02-11 2011-08-24 Biogen Idec MA Inc. Heterologous polypeptide of the tnf family
IL150755A0 (en) 2000-02-16 2003-02-12 Genentech Inc Uses of agonists and antagonists to modulate activity of tnf-related molecules
AU2006201471B2 (en) * 2000-02-16 2009-07-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of TNF-related molecules
AU2001261557B2 (en) * 2000-05-12 2005-06-30 Amgen Inc. Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
WO2001096528A2 (en) * 2000-06-15 2001-12-20 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
UA83458C2 (ru) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Выделенный полипептид baff-r (рецептор фактора активации в-клеток семейства tnf)
GB2370273A (en) * 2000-12-20 2002-06-26 Viaxxel Biotech Gmbh Compounds that affect CD83 expression
KR101021124B1 (ko) 2001-05-24 2011-03-14 지모제넥틱스, 인코포레이티드 Ｔａｃｉ-면역글로불린 융합 단백질
AU2002311976A1 (en) 2001-05-24 2002-12-03 Human Genome Sciences, Inc. Antibodies against tumor necrosis factor delta (april)
US7381792B2 (en) 2002-01-04 2008-06-03 Xencor, Inc. Variants of RANKL protein
WO2003057856A2 (en) 2002-01-04 2003-07-17 Xencor Dominant negative proteins and methods thereof
US7553930B2 (en) 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
WO2004089982A2 (en) * 2003-01-06 2004-10-21 Xencor April variants and methods thereof
CA2520097C (en) 2003-03-28 2014-10-07 Biogen Idec Ma Inc. Truncated baff receptors
CA2554526A1 (en) * 2004-01-29 2005-08-18 Genentech, Inc. Variants of the extracellular domain of bcma and uses thereof
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
WO2005113598A2 (en) * 2004-05-21 2005-12-01 Xencor, Inc. Tnf super family members with altered immunogenicity
CA2590461A1 (en) 2004-12-23 2006-06-29 Laboratoires Serono S.A. Bcma polypeptides and uses thereof
JP5118037B2 (ja) 2005-08-09 2013-01-16 ザイモジェネティクス， インコーポレイテッド Ｔａｃｉ融合分子を用いた異常細胞増殖の処置及び予防のための方法
ZA200801354B (en) 2005-08-09 2009-08-26 Ares Trading Sa Methods for treating B-cell malignancies using TACI-lg fusion molecule
DE602006020467D1 (de) * 2005-09-26 2011-04-14 Enzo Life Sciences Els Ag Antikörper gegen april als biomarker zur frühen prognose in lymphompatienten
EA015860B1 (ru) 2005-10-13 2011-12-30 Хьюман Дженом Сайенсиз, Инк. Способы лечения аутоиммунных заболеваний при использовании антагониста нейтрокина-альфа
AU2006318539B2 (en) 2005-11-23 2012-09-13 Genentech, Inc. Methods and compositions related to B cell assays
BRPI0711823A2 (pt) 2006-05-15 2012-01-17 Ares Trading Sa métodos para tratamento de doenças auto-imunes com uma molécula de fusão taci-ig
AU2010220421B9 (en) 2009-03-02 2015-03-05 Aduro Biotech Holdings, Europe B.V. Antibodies against a proliferating inducing ligand (APRIL)
EP2542679A1 (en) * 2010-03-05 2013-01-09 Academisch Medisch Centrum bij de Universiteit van Amsterdam B-cell stimulating fusion proteins of an antigen with baff or april
WO2011109280A1 (en) 2010-03-05 2011-09-09 Lerner Research Institute Methods and compositions to treat immune-mediated disorders
NL2011406C2 (en) * 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
EP2922394B1 (en) * 2013-09-23 2017-02-22 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized signal-regulatory protein gene
GB201317929D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
US20150143559A1 (en) * 2013-11-19 2015-05-21 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized a proliferation-inducing ligand gene
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
SI3380522T1 (sl) 2015-11-25 2024-02-29 Visterra, Inc. Molekule protitelesa proti APRIL in uporabe le-teh
AU2021370895A1 (en) 2020-10-29 2023-06-08 Industrial Polymers and Chemicals, Inc. Air filter with pathogen monitoring and inactivation
KR20240053675A (ko) 2021-08-11 2024-04-24 악소 바이오파마슈티컬 인코포레이티드 sBCMA 변이체 및 이의 FC 융합 단백질을 이용한 IgA, IgM 및/또는 IgG의 생산 감소 방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5176996A (en) * 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) * 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) * 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
WO1996040774A1 (en) * 1995-06-07 1996-12-19 Biogen, Inc. Complexes of modified lymphotoxins as pharmaceutical preparations
CN1214050A (zh) * 1996-03-14 1999-04-14 人体基因组科学有限公司 人肿瘤坏死因子δ和ε
US6509170B1 (en) * 1996-03-14 2003-01-21 Human Genome Sciences, Inc. Polynucleotides encoding human tumor necrosis factor delta
US6171787B1 (en) * 1997-06-26 2001-01-09 Abbott Laboratories Member of the TNF family useful for treatment and diagnosis of disease

Also Published As

Publication number Publication date
EP1027431A2 (en) 2000-08-16
NO20001242D0 (no) 2000-03-09
CN1270632A (zh) 2000-10-18
HUP0004611A2 (hu) 2001-04-28
IS5378A (is) 2000-02-18
CA2303615A1 (en) 1999-03-18
CN1195849C (zh) 2005-04-06
NO20001242L (no) 2000-05-11
AU9316298A (en) 1999-03-29
HUP0004611A3 (en) 2002-04-29
IL134537A0 (en) 2001-04-30
EA200000310A1 (ru) 2000-10-30
SK3542000A3 (en) 2000-08-14
TR200000669T2 (tr) 2000-08-21
US20060084148A1 (en) 2006-04-20
US20050112596A1 (en) 2005-05-26
KR100618492B1 (ko) 2006-08-31
KR20010023893A (ko) 2001-03-26
WO1999012965A2 (en) 1999-03-18
EA005411B1 (ru) 2005-02-24
CZ2000869A3 (cs) 2000-09-13
BR9812634A (pt) 2000-08-22
JP2001515712A (ja) 2001-09-25
US20030138884A1 (en) 2003-07-24
AU759717B2 (en) 2003-04-17
NZ503850A (en) 2002-12-20
CZ294615B6 (cs) 2005-02-16
WO1999012965A3 (en) 1999-06-03
PL339463A1 (en) 2000-12-18

Similar Documents

Publication Publication Date Title
EE200000147A (et) April - uus kasvuefekte omav valk
NO983364L (no) Konsensusproteiner
NO2010022I1 (no) Denosumab
DE69839603D1 (de) Zierenden proteins
DE69800491D1 (de) Baumschere
DK0988861T3 (da) Stabiliserede proteinpræparater
DE69820156D1 (de) VErbessertes monofilament
DE69824232D1 (de) Gefriergerät
DE69802241D1 (de) Mähmaschine
DE59706733D1 (de) Erntemaschine
DE69833493D1 (de) Gewebe
DK0832553T3 (da) Mejetærsker
DE59705517D1 (de) Mähdrescher
FR2747908B1 (fr) Suture irrigatrice
ID22391A (id) Alat pendingin
ATE295417T1 (de) Angiostatin-bindendes protein
DE59808209D1 (de) Mähdrescher
TR199701666A3 (tr) Sismanliga karsi proteinler
DE69704693D1 (de) Mähdrescher
DE59809449D1 (de) Mähdrescher
DE69614821D1 (de) Geschalteter Taktgeber
KR980000103U (ko) 자라사육기
DE69636232D1 (de) Wachstumsfaktor htter36
ATA126198A (de) Mähwerk
DE69801101D1 (de) Kraftzange

Legal Events

Date Code Title Description
HC1A Change of owner name